Since then, Novo Nordisk (Wegovy and Ozempic) and Eli Lilly (Mounjaro and Zepbound ... “impurities,” the use of an untested “salt” form of semaglutide in compounded drugs, and “adverse events,” which ...

Since then, Novo Nordisk (Wegovy and Ozempic) and Eli Lilly (Mounjaro and Zepbound ... an untested “salt” form of semaglutide in compounded drugs, and “adverse events,” which encompass ...

Eli Lilly has begun the week with a bang ... Tirzepatide, the GLP-1 drug in Mounjaro and Zepbound, is Lilly’s highest-profile MASH candidate. Lilly reported phase 2 MASH data in June and ...

Eli Lilly’s profit doubled in ... better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend growth stocks. Dividend stocks faced a tough year in 2024 as investor focus ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In an era where financial literacy is increasingly recognized as a crucial ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... driven by the strong performance of its GLP-1 drugs, Mounjaro and Zepbound. These medications have ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... driven by strong volume growth from Mounjaro and Zepbound. Earnings per share (EPS) for the quarter doubled ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...

Major stock indexes closed lower on Friday, after the week saw a flurry of corporate earnings reports from major tech firms, including Alphabet and Amazon. The healthcare industry also had its ...